The Dilated Cardiomyopathy Market Size in the 7MM is expected to increase at a CAGR of 13.1% for the study period 2017-30. Dilated Cardiomyopathy (DCM) is one of the most common types of cardiomyopathies, i.e., diseases of heart muscles. Dilated Cardiomyopathy is a disease that results from the stretching and e...
Find MoreMyoKardia has announced the promising results of Phase III clinical trials of its lead drug mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Following the announcement, shares of the California-based company skyrocketed. The Phase III clinical trial - EXPLORER-HCM – demonstrated the pot...
Find MoreFailure of Phase II cannabidiol trial leads to loss for Zynerba Zynerba Pharmaceuticals’ phase II trial for transdermal cannabinoid candidate missed all its endpoints, as it failed to hit a single goal or show a dose response raises big doubts about the drug's prospects. This news eroded around 55% off Zynerba’s sto...
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!